<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074295</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000343797</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0310</secondary_id>
    <nct_id>NCT00074295</nct_id>
  </id_info>
  <brief_title>S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer</brief_title>
  <official_title>Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor tissue may make the body build an immune&#xD;
      response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating&#xD;
      patients with stage IIIB or stage IV bronchoalveolar (lung) cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients with selected stage IIIB&#xD;
           or stage IV bronchoalveolar carcinoma treated with GVAX lung cancer vaccine.&#xD;
&#xD;
        -  Determine the response rate (confirmed and unconfirmed and complete and partial) in&#xD;
           patients treated with this vaccine.&#xD;
&#xD;
        -  Determine the frequency and severity of toxic effects of this vaccine in these patients.&#xD;
&#xD;
        -  Determine the functional status of patients treated with this vaccine.&#xD;
&#xD;
        -  Correlate systemic biologic activity (i.e., antigen-specific antitumor and systemic&#xD;
           cytokine responses) with clinical outcome in patients treated with this vaccine.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior systemic&#xD;
      cancer therapy for bronchoalveolar carcinoma (BAC) (yes vs no) and pattern of BAC (diffuse vs&#xD;
      nodular).&#xD;
&#xD;
      After successful vaccine manufacturing from tumor tissue procured, patients receive GVAX lung&#xD;
      cancer vaccine intradermally (ID) (6-7 injections per vaccination) on weeks 1, 3, 5, 7, and 9&#xD;
      for a total of 5 vaccinations. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and at weeks 9, 13, and 21.&#xD;
&#xD;
      Patients are followed at 4 weeks, every 8 weeks for 1 year, and then every 12 weeks for 2&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 117 patients (67 previously untreated and 50 previously&#xD;
      treated) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    closed due to lack of availability of vaccine&#xD;
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free and overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional status</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of systemic biologic activity with clinical outcome</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GVAX lung cancer vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVAX lung cancer vaccine</intervention_name>
    <description>6-7 injections per week in rotating locations for five weeks</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>CG8123</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis* of 1 of the following by radiological features and clinical presentation:&#xD;
&#xD;
               -  Bronchoalveolar carcinoma (BAC)&#xD;
&#xD;
                    -  Diffuse or ground glass appearance&#xD;
&#xD;
               -  Adenocarcinoma with bronchoalveolar features&#xD;
&#xD;
               -  BAC with focal invasion NOTE: *Histological confirmation (excluding fine needle&#xD;
                  aspiration or bronchial brushings or washings) is required after the tumor tissue&#xD;
                  has been procured and the vaccine has been produced&#xD;
&#xD;
          -  Selected stage IIIB (due to malignant pleural effusion) OR stage IV disease&#xD;
&#xD;
          -  Measurable or nonmeasurable disease (e.g., diffuse infiltrative process) by CT scan of&#xD;
             the chest both before and after tumor tissue procurement for vaccine&#xD;
&#xD;
          -  Not a candidate for curative resection&#xD;
&#xD;
          -  Tumor accessible for tissue procurement via thoracentesis or a surgical procedure&#xD;
&#xD;
               -  If a pleural effusion is the source of tumor tissue, at least 600 mL of fluid&#xD;
                  must be available for vaccine manufacture&#xD;
&#xD;
               -  Resection of brain metastases may be used for vaccine processing&#xD;
&#xD;
                    -  Surgery must be done after study entry&#xD;
&#xD;
          -  Asymptomatic previously treated (e.g., surgical resection or radiotherapy) brain&#xD;
             metastases allowed provided the patient is neurologically stable&#xD;
&#xD;
          -  No active or impending spinal cord compression or evidence of pericardial tamponade&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  CD4 count greater than 200/mm^3&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if liver&#xD;
             metastases are present)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if bone metastases are&#xD;
             present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Patients requiring surgery for tumor tissue procurement must meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  Pulmonary artery systolic pressure &lt; 40 mm Hg by echocardiogram*&#xD;
&#xD;
               -  LVEF &gt; 40%&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No thrombolic disorder&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia NOTE: *Not needed if patient has no tricuspid regurgitation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary hypertension&#xD;
&#xD;
          -  No significant baseline hypoxia (i.e., O_2 saturation less than 90% OR requires&#xD;
             greater than 2 L/min of supplemental O_2 via nasal cannula) by an oxygen saturation&#xD;
             test&#xD;
&#xD;
          -  No postobstructive pneumonia&#xD;
&#xD;
          -  Patients requiring thoracoscopic surgery or thoracotomy for tumor tissue procurement&#xD;
             must meet the following criteria:&#xD;
&#xD;
               -  Alveolar partial pressure of CO_2 &lt; 45 mm Hg&#xD;
&#xD;
               -  Predicted postresection FEV_1 â‰¥ 1.0 L&#xD;
&#xD;
               -  DLCO &gt; 50% of predicted&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active immune or autoimmune disease&#xD;
&#xD;
          -  No systemic lupus erythematosus&#xD;
&#xD;
          -  No sarcoiditis&#xD;
&#xD;
          -  No rheumatoid arthritis&#xD;
&#xD;
          -  No glomerulonephritis&#xD;
&#xD;
          -  No vasculitis&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No hypersensitivity to any of the following:&#xD;
&#xD;
               -  Sargramostim (GM-CSF)&#xD;
&#xD;
               -  Pentastarch&#xD;
&#xD;
               -  Gentamicin&#xD;
&#xD;
               -  Human serum albumin&#xD;
&#xD;
               -  Dimethyl sulfoxide&#xD;
&#xD;
               -  Porcine trypsin&#xD;
&#xD;
               -  Fetal bovine serum&#xD;
&#xD;
               -  Recombinant benzonase&#xD;
&#xD;
               -  Other components of the vaccine or CG6444 adenoviral vector used in this study&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No poor nutritional status&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance or&#xD;
             increase operative risk&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer currently in complete remission&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No prior gene therapy, including adenoviral-based therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
               -  No prior regional chemotherapy administered through the pulmonary artery (if&#xD;
                  resection of the tumor in the treated lobe is planned)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 14 days since prior systemic corticosteroids&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteistics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
               -  Disease must be outside the areas of prior radiotherapy OR clear progression at&#xD;
                  prior irradiated sites must be documented&#xD;
&#xD;
          -  No prior radiotherapy to the tumor mass targeted for resection&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 7 days since prior surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior epidermal growth factor receptor inhibitors&#xD;
&#xD;
          -  No other concurrent nonprotocol-specified treatment&#xD;
&#xD;
          -  No concurrent immunosuppressants&#xD;
&#xD;
          -  No concurrent chronic anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raja Mudad, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University Health Sciences Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

